Synergistic activities of three triazoles with caspofungin against candida glabrata isolates determined by time-kill, etest, and disk diffusion methods

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 2244-2247

  Kiraz, Nuri ^a   Dag, Ilknur ^a   Yamac, Mustafa ^a   Kiremitci, Abdurrahman ^a   Kasifoglu, Nilgun ^a   Oz, Yasemin ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA GLABRATA; CONTROLLED STUDY; DISK DIFFUSION; DRUG POTENTIATION; EPSILOMETER TEST; FUNGUS CULTURE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA GLABRATA; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; ECHINOCANDINS; ENDPOINT DETERMINATION; FLUCONAZOLE; ITRACONAZOLE; PYRIMIDINES; TIME FACTORS; TRIAZOLES;

EID: 77951239005     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01527-09     Document Type: Article

References (23)

1. Alexander, B., T. C. Byrne, K. L. Smith, K. E. Hanson, K. J. Anstrom, J. R. Perfect, and L. B. Reler. 2007. Comparative evaluation of Etest and Sensititre YeastOne panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J. Clin. Microbiol. 45:698-706.
2. Baltch, A. L., L. H. Bopp, R. P. Smith, W. J. Ritz, and P. B. Michelsen. 2008. Anticandidal effects of voriconazole and caspofungin, singly and in combination, against Candida glabrata, extracellularly and intracellularly in granulocyte-macrophage colony stimulating factor (GM-CSF)-activated human monocytes. J. Antimicrob. Chemother. 62:1285-1290.
3. Barchiesi, F., E. Spreghini, M. Maracci, A. W. Fothergill, I. Baldassarri, M. G. Rinaldi, and G. Scalise. 2004. In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. Antimicrob. Agents Chemother. 48:3317-3322.
4. Barchiesi, F., E. Spreghini, S. Tomassetti, D. Giannini, and G. Scalise. 2007. Caspofungin in combination with amphotericin B against Candida parapsilosis. Antimicrob. Agents Chemother. 51:941-945.
5. Canton, E., A. Espinel-Ingroff, and J. Peman. 2009. Trends in antifungal susceptibility testing using CLSI reference and commercial methods. Expert Rev. Anti Infect. Ther. 7:107-119.
6. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard - third edition. Document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute/NCCLS. 2004. Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline - second edition. Document M44-A2. Clinical and Laboratory Standards Institute/ NCCLS, Wayne, PA.
8. Cuenca-Estrella, M., A. Gomez-Lopez, G. Garcia-Effron, L. Alcazar-Fuoli, E. Mellado, J. M. Buitrago, and J. L. Rodriguez-Tudela. 2005. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob. Agents Chemother. 49:1232-1235.
9. Dias, A. L. T., F. E. Matsumoto, M. S. C. Melhem, E. G. Silva, M. E. Auler, A. M. Siqueira, and C. R. Paula. 2006. Comparative analysis of Etest and broth microdilution method (AFST-EUCAST) for trends in antifungal drug susceptibility testing of Brazilian Cryptococcus neoformans isolates. J. Med. Microbiol. 55:1693-1699.
10. Fidel, P. L., J. A. Vazquez, and J. D. Sobel. 1999. C. glabrata. Review of epidemiology, pathogenesis and clinical disease with comparison to Candida albicans. Clin. Microbiol. Rev. 12:80-86.
11. Kiraz, N., I. Dag, M. Yamac, A. Kiremitci, N. Kaçsifoǧlu, and Y. Akgun. 2009. Antifungal activity of caspofungin in combination with amphotericin B against Candida glabrata: comparison of disk diffusion, Etest, and time-kill methods. Antimicrob. Agents Chemother. 53:788-790.
12. Koehler, A. P., K. C. Chu, E. T. Houang, and A. F. Cheng. 1999. Simple, reliable, and cost-effective yeast identification scheme for the clinical laboratory. J. Clin. Microbiol. 37:422-426.
13. López-Ciudad, V., M. J. Castro-Orjales, C. León, et al. 2006. Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole. BMC Infect. Dis. 6:73.
14. Lozano-Chiu, M., P. W. Nelson, V. L. Paetznick, and J. H. Rex. 1999. Disk diffusion method for determining susceptibilities of Candida spp. to MK- 0991. J. Clin. Microbiol. 37:1625-1627.
15. Mariné, M., C. Serena, F. J. Pastor, and J. Guarro. 2006. Combined antifungal therapy in a murine infection by Candida glabrata. J. Antimicrob. Chemother. 58:1295-1298.
16. Oliveira, E. R., A. W. Fothergill, W. R. Kirkpatrick, B. J. Coco, T. F. Patterson, and S. W. Redding. 2005. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata. Antimicrob. Agents Chemother. 49:3544-3545.
17. Pankey, G. A., and D. S. Ashcraft. 2005. In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:2959-2964.
18. Perea, S., G. Gonzalez, A. W. Fothergill, W. R. Kirkpatrick, M. G. Rinaldi, and T. F. Patterson. 2002. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. 46:3039-3041.
19. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2006. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. 44:760-763.
20. Rodríguez, M. M., M. Ruiz, F. J. Pastor, G. Quindós, A. Carrillo, and G. Guarro. 2007. In vitro interaction of micafungin and fluconazole against Candida. J. Antimicrob. Chemother. 60:188-190.
21. Silici, S., N. A. Koc, D. Ayangil, and S. Cankaya. 2005. Antifungal activities of propolis collected by different races of honeybees against yeasts isolated from patients with superficial mycoses. J. Pharmacol. Sci. 99:39-44.
22. White, R. L., D. S. Burgess, M. Manduru, and J. A. Bosso. 1996. Comparison of three different in vitro methods of detecting synergy: time-kill, checker-board, and E-test. Antimicrob. Agents Chemother. 40:1914-1918.
23. Yan, L., M. Li, Y. Cao, P. Gao, Y. Wang, and Y. Jiang. 2009. The alternative oxidase of Candida albicans causes reduced fluconazole susceptibility. J. Antimicrob. Chemother. 64:764-773.